ClinicalTrials HQ

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting · NCT05573126 · Registry updated 2026-06-22
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorderRecruitingPhase 1 / Phase 22026-06-22NCT05573126

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Ellipses Pharma4

14 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Henry Ford HospitalDetroitUnited States326
Hospital 12 de OctubreUseraSpain1
Hospital Universitari Vall d'Hebron (VHIO)BarcelonaSpain1
Hospital Universitario Ramón y CajalMadridSpain87
Massachusetts General HospitalBostonUnited States1015
Moffitt Cancer CenterTampaUnited States523
NEXT Oncology Hospital QuironsaludMadridSpain1
Sarah Cannon Research InstituteNashvilleUnited States119
Sarah Cannon Research Institute UKLondonUnited Kingdom1
Texas Oncology Baylor University Medical CenterDallasUnited States1
The Christie NHS Foundation TrustManchesterUnited Kingdom1
The Clatterbridge Cancer CentreLiverpoolUnited Kingdom1
Virginia Cancer SpecialistsFairfaxUnited States109
Yale School of MedicineNew HavenUnited States17